{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T23:44:30Z","timestamp":1794008670205,"version":"4.8.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"UCL\/UCLH NIHR Biomedical Research Centre"},{"name":"Pharma Mar S.A."},{"name":"Centro para el Desarrollo Tecnol\u00f3gico Industrial"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1136\/ijgc-2021-002881","type":"journal-article","created":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T18:02:29Z","timestamp":1633456949000},"page":"1428-1436","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study"],"prefix":"10.1016","volume":"31","clinical-trial-number":[{"clinical-trial-number":"nct01970540","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03884101","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03517449","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01970540","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01767155","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01970540","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct01767155","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Rebecca","family":"Kristeleit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Boni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva M","family":"Guerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Kahatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neus","family":"Bast\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A","family":"L\u00f3pez-Vilari\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Siguero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-2390","authenticated-orcid":false,"given":"Vicente","family":"Alfaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Zeaiter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2021-002881_bb0010","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1097\/IGC.0b013e3182915c20","article-title":"Treatment of advanced or recurrent endometrial carcinoma with doxorubicin in patients progressing after paclitaxel\/carboplatin: Memorial Sloan-Kettering cancer center experience from 1995 to 2009","volume":"23","author":"Makker","year":"2013","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002881_bb0015","year":"2021","journal-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): uterine neoplasms. version 03"},{"key":"10.1136\/ijgc-2021-002881_bb0020","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.17408.1","article-title":"Recent advances in endometrial cancer: a review of key clinical trials from 2015 to 2019","volume":"8","author":"Charo","year":"2019","journal-title":"F1000Res"},{"key":"10.1136\/ijgc-2021-002881_bb0025","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000474","article-title":"Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer","volume":"4","author":"Fountzilas","year":"2019","journal-title":"ESMO Open"},{"key":"10.1136\/ijgc-2021-002881_bb0030","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1158\/1078-0432.CCR-20-3901","article-title":"FDA approval summary: Lurbinectedin for the treatment of metastatic small cell lung cancer","volume":"27","author":"Singh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-002881_bb0035","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1158\/1078-0432.CCR-13-1880","article-title":"First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors","volume":"20","author":"Elez","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-002881_bb0040","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1093\/annonc\/mdx357","article-title":"Antitumor activity of lurbinectedin (PM01183) and doxorubicin in relapsed small-cell lung cancer: results from a phase I study","volume":"28","author":"Calvo","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0045","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1056\/NEJM199809243391307","article-title":"Doxorubicin-induced cardiomyopathy","volume":"339","author":"Singal","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1136\/ijgc-2021-002881_bb0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ejca.2004.09.026","article-title":"Chemotherapy-induced nausea and vomiting: current and new standards in the antiemetic prophylaxis and treatment","volume":"41","author":"Jordan","year":"2005","journal-title":"Eur J Cancer"},{"key":"10.1136\/ijgc-2021-002881_bb0055","first-page":"1121","article-title":"Clinical endpoints in oncology - a primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am J Cancer Res"},{"key":"10.1136\/ijgc-2021-002881_bb0060","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s10637-020-01025-x","article-title":"Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. results from an expansion cohort of a phase I study","volume":"39","author":"Olmedo","year":"2021","journal-title":"Invest New Drugs"},{"key":"10.1136\/ijgc-2021-002881_bb0065","doi-asserted-by":"crossref","first-page":"5062","DOI":"10.1158\/1078-0432.CCR-19-3979","article-title":"FDA approval summary: pembrolizumab plus lenvatinib for endometrial carcinoma, a collaborative international review under project Orbis","volume":"26","author":"Arora","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1136\/ijgc-2021-002881_bb0070","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1200\/JCO.19.02627","article-title":"Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer","volume":"38","author":"Makker","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0075","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ygyno.2015.04.026","article-title":"Phase III randomized trial of second-line ixabepilone versus paclitaxel or doxorubicin in women with advanced endometrial cancer","volume":"138","author":"McMeekin","year":"2015","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0080","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1200\/JCO.2010.32.6397","article-title":"Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a gynecologic Oncology Group study","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0085","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.5586","article-title":"Activity of lurbinectedin (PM01183) as single agent and in combination in patients with endometrial cancer","volume":"35","author":"Forster","year":"2017","journal-title":"JCO"},{"key":"10.1136\/ijgc-2021-002881_bb0090","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.5503","article-title":"ZoptEC: phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155)","volume":"36","author":"Miller","year":"2018","journal-title":"JCO"},{"key":"10.1136\/ijgc-2021-002881_bb0095","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1200\/OP.20.00924","article-title":"Monitoring for chemotherapy-related cardiotoxicity in the form of left ventricular systolic dysfunction: a review of current recommendations","volume":"17","author":"Stone","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"10.1136\/ijgc-2021-002881_bb0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00000421-198406000-00010","article-title":"Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group study","volume":"7","author":"Thigpen","year":"1984","journal-title":"Am J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0105","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0301-2115(99)00066-4","article-title":"Cyclophosphamide or ifosfamide in patients with advanced and\/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group","volume":"86","author":"Pawinski","year":"1999","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1136\/ijgc-2021-002881_bb0110","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1006\/gyno.1999.5652","article-title":"Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group","volume":"75","author":"Moore","year":"1999","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0115","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ygyno.2008.06.013","article-title":"A phase II evaluation of Weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the gynecologic Oncology Group","volume":"111","author":"Garcia","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0120","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1097\/IGC.0b013e31822d754e","article-title":"Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer","volume":"21","author":"Di Legge","year":"2011","journal-title":"Int J Gynecol Cancer"},{"key":"10.1136\/ijgc-2021-002881_bb0125","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1200\/JCO.2002.08.171","article-title":"Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study","volume":"20","author":"Muggia","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0130","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s00432-003-0497-8","article-title":"Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer","volume":"129","author":"Escobar","year":"2003","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0135","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1006\/gyno.1996.0286","article-title":"A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"63","author":"Rose","year":"1996","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0140","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ygyno.2010.11.027","article-title":"A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study","volume":"121","author":"Tait","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0145","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1002\/1097-0142(19940301)73:5<1453::AID-CNCR2820730521>3.0.CO;2-X","article-title":"Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. A Gynecologic Oncology Group study","volume":"73","author":"Sutton","year":"1994","journal-title":"Cancer"},{"key":"10.1136\/ijgc-2021-002881_bb0150","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1200\/JCO.2008.20.6995","article-title":"Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P","volume":"27","author":"Dizon","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0155","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.ygyno.2006.03.043","article-title":"Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study","volume":"103","author":"Fracasso","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0160","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0090-8258(02)00068-9","article-title":"Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a gynecologic Oncology Group study","volume":"88","author":"Lincoln","year":"2003","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2021-002881_bb0165","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1006\/gyno.2002.6804","article-title":"A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study","volume":"87","author":"Miller","year":"2002","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24021352?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24021352?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2021-002881","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T22:39:49Z","timestamp":1753223989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24021352"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1048891X24021352"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2021-002881","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2021-002881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/.","name":"copyright","label":"Copyright"}]}}